Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Candel Therapeutics, Inc.NASDAQ: CADL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $149K fell 39.2% year over year, behind the -23.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -39.2% toward the trailing-twelve-month pace of -23.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 845K USD
- Year-over-year change
- -14.6%
- 4-year CAGR
- +38.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 845K | -14.6% |
| FY2024 | 2024-12-31 | 990K | -22.8% |
| FY2023 | 2023-12-31 | 1.28M | +64.9% |
| FY2022 | 2022-12-31 | 778K | +235.3% |
| FY2021 | 2021-12-31 | 232K | — |
Depreciation & Amortization vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -23.9% is the 7th highest of 9, against a peer median of -4.6%.
- Over three fiscal years its annual growth of +2.8% compares with a peer median of +3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $33.47M USD | -27.6% | +30.8% | 8.8% | |
| LTM Mar 2026 | $12.88M USD | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $10.73M USD | -6.1% | +3.6% | 4.7% | |
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥1.54M CNY | — | -76.2% | — |
| LTM Mar 2026 | $1.19M USD | +3.5% | +8.1% | — | |
| LTM Mar 2026 | $749K USD | -23.9% | +2.8% | — | |
| LTM Mar 2026 | $436.09K USD | +189.3% | +454.8% | — | |
| LTM Mar 2026 | $102K USD | -2140.0% | -43.3% | 0.0% | |
GNLXGenelux Corporation | LTM Mar 2026 | $44K USD | +116.9% | -36.8% | 550.0% |
| Peer median (excluding CADL) | — | -4.6% | +3.6% | 4.7% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Depreciation & Amortization | 232K | 778K | 1.28M | 990K | 845K |
| Deferred Income Tax | 11.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.96M | 2.31M | 3.09M | 5.31M | 3.82M |
| Change in Working Capital | (876K) | 71K | (378K) | 346K | 2.19M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 669K | (1.21M) | 45K | (185K) | 802K |
| Other Working Capital | (1.55M) | 1.28M | (378K) | 531K | 1.39M |
| Other Non-Cash Items | 76K | (15.78M) | (301K) | 21.51M | (6.98M) |
| Operating Cash Flow | (22.22M) | (31.42M) | (34.24M) | (27.02M) | (38.31M) |
| Capital Expenditures | (1.84M) | (1.3M) | (457K) | (16K) | (587K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 27K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 177K | 0 | 0 |
| Investing Cash Flow | (1.84M) | (1.3M) | (280K) | (16K) | (560K) |
| Debt Repayment | 0 | 19.91M | 0 | (9.17M) | 36.21M |
| Common Stock Issued | 71.34M | 0 | 0 | 101.76M | 19.89M |
| Common Stock Repurchased | 0 | 0 | (121K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 465K | 64K | 0 | 1.69M | 0 |
| Financing Cash Flow | 71.8M | 19.97M | (121K) | 94.28M | 56.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47.75M | (12.74M) | (34.65M) | 67.24M | 17.23M |
| Free Cash Flow | (24.05M) | (32.72M) | (34.7M) | (27.04M) | (38.9M) |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.